Cross-source identity
National Provider Identifier 1124261177 as it appears in every federal dataset Fonteum holds. Each row is a distinct public source; the chip carries the source and the snapshot date behind that field — the record-level form of the source-provenanced graph.
| Federal source | Key | What it provides | Provenance |
|---|
| CMS NPPES | NPI 1124261177 | Registry identity — dermatologist, taxonomy 207NS0135X | Source:CMS NPPESSnapshot 2026-05-06 |
| CMS Open Payments | NPI 1124261177 | 182 industry-payment records, 2024 | Source:CMS Open PaymentsSnapshot PY2024 |
| CMS Medicare Part D | NPI 1124261177 | 32 drugs prescribed, 2024 | Source:CMS Part DSnapshot DY2024 |
| Fonteum entity graph | entity d09bf839… | Canonical resolved node · 4 identifier(s) · 18 edge(s) | Source:Entity graphSnapshot 2026-06-11 |
Industry payments
Payments and transfers of value this clinician received from drug and device manufacturers, disclosed under the Physician Payments Sunshine Act. A payment is a disclosure, not a judgment.
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $40,469 | 28 |
| Food and Beverage | $4,326 | 147 |
| Travel and Lodging | $425 | 5 |
| Education | $110 | 2 |
| Manufacturer | Amount | Records |
|---|---|---|
| Incyte Corporation | $25,839 | 32 |
| Pfizer Inc. | $6,740 | 17 |
| Dermavant Sciences, Inc. | $5,367 |
Prescribing
Prescriptions written under Medicare Part D, aggregated by drug across the program. Totals reflect claims paid, not patients treated.
| Drug | Claims | Drug cost |
|---|---|---|
| Dupixent Pen(Dupilumab) | 111 | $427,344 |
| Tremfya(Guselkumab) | 15 | $202,981 |
| Humira Pen(Adalimumab) | 13 | $90,734 |
| Humira(Cf) Pen(Adalimumab) | 13 | $88,525 |
| Dupixent Syringe(Dupilumab) | 13 | $57,382 |
Beneficiary counts below 11 are suppressed by CMS — the total shown is a lower bound.
Quality
CMS Quality Payment Program Merit-based Incentive Payment System (MIPS) final score, where this clinician participated. Absence of a score is not a quality signal — many clinicians report through a group or are exempt.
Enrollment & sanctions
Screening aid — re-confirm any match against the issuing list before acting. A clean result means no record was found in the federal OIG LEIE or the state Medicaid lists Fonteum currently holds (NY, OH, GA), not a guarantee that none exists elsewhere. Not a legal or credentialing certification.
Ownership & affiliations
One-hop relationships in the resolved entity graph — chain membership, ownership, and operation edges, each backed by a federal source row. Most individual clinicians carry none; edges populate for owners and organizations as the Lane D backfill runs.
| Relationship | Entity | Source |
|---|---|---|
| ← pays | Janssen Biotech, Inc. (PA) | cms_open_payments |
| ← pays | Novartis Pharmaceuticals Corporation (NJ) | cms_open_payments |
| ← pays | Medimetriks Pharmaceuticals, Inc. (NJ) | cms_open_payments |
| ← pays | Journey Medical Corporation (AZ) | cms_open_payments |
| ← pays | E.R. Squibb & Sons, L.L.C. (NJ) | cms_open_payments |
| ← pays | Abbvie Inc. (IL) | cms_open_payments |
| ← pays | Regeneron Healthcare Solutions, Inc. (NY) | cms_open_payments |
| ← pays | Amgen Inc. (CA) | cms_open_payments |
| ← pays | Boehringer Ingelheim Pharmaceuticals, Inc. (CT) | cms_open_payments |
| ← pays | Verrica Pharmaceuticals Inc. (PA) | cms_open_payments |
| ← pays | Almirall Llc (PA) | cms_open_payments |
| ← pays | Arcutis Biotherapeutics, Inc. (CA) | cms_open_payments |
| ← pays | Dermavant Sciences, Inc. (CA) | cms_open_payments |
| ← pays | Pfizer Inc. (NY) | cms_open_payments |
| ← pays | Lilly Usa, Llc (IN) | cms_open_payments |
| ← pays | Genzyme Corporation (MA) | cms_open_payments |
| ← pays | Sanofi-Aventis U.S. Llc (NJ) | cms_open_payments |
| ← pays | Incyte Corporation (DE) | cms_open_payments |
| 12 |
| Lilly Usa, Llc | $4,705 | 10 |
| Janssen Biotech, Inc. | $433 | 21 |